Entera Bio Ltd. (ENTX)

1.9800 -0.0200 (-1.00%) At close: 04:00PM EDT

Entera Bio Ltd.

Kiryat Hadassah Minrav Building
Fifth Floor
Jerusalem 9112002
Israel
972 2 532 7151
https://www.enterabio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Miranda J. Toledano M.B.A.	CEO & Director	418k	N/A	1977
Ms. Dana Yaacov-Garbeli CPA	Chief Financial Officer	193k	N/A	1983
Dr. Hillel Galitzer M.B.A., Ph.D.	Chief Operating Officer	296k	N/A	1978
Dr. Arthur C. Santora II, M.D., Ph.D.	Chief Medical Officer	355k	N/A	1951

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Corporate governance

Entera Bio Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.